Document is current
Any future updates will be listed below
-
Authors
Koc, Ali Can
Sari, Vedat
Kocak, Gamze
Recber, Tuba
Nemutlu, Emirhan
Aberdam, Daniel
Güven, Sinan
-
Funding
Funding for this research was provided by:
Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (BİDEB 2211-A, BİDEB 2211-A, 121N276)
YÖK (100/2000 PhD Scholarship, 100/2000 PhD Scholarship)
European Joint Programme on Rare Diseases
- License Information
-
More Information
Article History
Received: 16 September 2024
Accepted: 23 December 2024
First Online: 10 January 2025
Declarations
:
: Ethical approval for the use of patient-derived hiPSCs in this study was granted by the Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation (MESRI; IE-2018–967). The cell lines were subsequently registered in the Human Pluripotent Stem Cell Registry (hPSCreg) under the following identifiers: AAKIPSi001-A, AAKIPSi002-A, and AAKIPSi003-A. Written informed consents for collection, storage, and use of control iPSC for research purposes were obtained and the study is approved by the Instituonal Review Board of Hacettepe University (Study approval number: 16969557–1213).
: Not applicable.
: The authors declare no competing interests.
